Cargando…
THU455 Sclerostin Inhibitor Use In The Medical Management Of Osteogenesis Imperfecta Type III
Disclosure: M.D. Lundholm: None. A. Derkyi: None. S. Talvacchio: None. J.C. Marini: Other; Self; Ultragenyx, Amgen Inc. L.Z. Khan: None. Background: Osteogenesis imperfecta (OI) is a rare collagen-related hereditary skeletal disorder with an increased fracture risk from minimal trauma, short stature...
Autores principales: | Lundholm, Michelle Diane, Derkyi, Alberta, Talvacchio, Sara, Marini, Joan Carol, Khan, Leila Zeinab |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554595/ http://dx.doi.org/10.1210/jendso/bvad114.416 |
Ejemplares similares
-
THU456 Beyond Guidelines: Treatment Of Concurrent Osteogenesis Imperfecta And Metastatic Bone Disease
por: Kanin, Maralee, et al.
Publicado: (2023) -
Osteogenesis Imperfecta With Cerebral Atherosclerosis: A Family Report
por: He, Junyu, et al.
Publicado: (2021) -
Lung Transplantation in a Patient With Osteogenesis Imperfecta and Osteoporosis
por: Fan, Lena, et al.
Publicado: (2021) -
SUN-LB66 Oral Risedronate Treatment in Children With Osteogenesis Imperfecta
por: Nguyen, Antoine T, et al.
Publicado: (2020) -
THU459 Hypophosphatasia With Normal ALPL Gene Test; A Case Report
por: Alkwatli, Kenda, et al.
Publicado: (2023)